NCT07522476 2026-04-13
A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma
Virogin Biotech Ltd.
Phase 2 Not yet recruiting
Clinical Trials
16 trialsNCT07514533 2026-04-07
The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma
Sir Run Run Shaw Hospital
Phase 2 Not yet recruiting
NCT07478523 2026-03-17
FAPDIG
University Hospital, Bordeaux
Phase 2 Not yet recruiting
NCT07432568 2026-02-25
A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07353827 2026-01-20
FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07296666 2025-12-22
Adjuvant Chemotherapy for BTC Based on 3D-PTA
Fudan University
Phase 2 Not yet recruiting
NCT07128290 2025-08-17
PEHRICCA
Federation Francophone de Cancerologie Digestive
Phase 2 Not yet recruiting
NCT07030140 2025-06-22
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
Shandong Cancer Hospital and Institute
Phase 2 Not yet recruiting
NCT05039892 2025-05-20
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma
3D Medicines
Phase 2 Not yet recruiting
NCT06946849 2025-04-27
SED-RO-ICC
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT06903273 2025-03-30
TisGCS for BTC
National Cheng-Kung University Hospital
Phase 2 Not yet recruiting
NCT06648525 2024-10-18
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC
Harbin Medical University
Phase 2 Not yet recruiting
NCT06567600 2024-08-22
Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT06530823 2024-07-31
Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma
Eastern Hepatobiliary Surgery Hospital
Phase 2 Not yet recruiting
NCT06519110 2024-07-25
CVL009-C2001
Convalife (Shanghai) Co., Ltd.
Phase 2 Not yet recruiting
NCT06375642 2024-04-19
A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting